Cargando…

SARS-CoV-2 mRNA-based vaccines in the Aicardi Goutières Syndrome

Aicardi Goutières Syndrome (AGS) is an autoinflammatory disorder resulting in sustained interferon activation through defects in nucleic acid modification and sensing pathways. Thus, mRNA-based vaccination used against SARS-CoV-2, raise disease-specific safety concerns. To assess interferon signalin...

Descripción completa

Detalles Bibliográficos
Autores principales: Takanohashi, Asako, Alameh, Mohamad-Gabriel, Woidill, Sarah, Hacker, Julia, Davis, Benjamin, Helman, Guy, Gavazzi, Francesco, Adang, Laura, D'Aiello, Russell, Winters, Patrick, Cordova, Devon, Khandaker, Taibeen, Ni, Houping, Tam, Ying, Lin, Paulo, Weissman, Drew, Shults, Justine, Vanderver, Adeline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550281/
https://www.ncbi.nlm.nih.gov/pubmed/36334423
http://dx.doi.org/10.1016/j.ymgme.2022.10.001
Descripción
Sumario:Aicardi Goutières Syndrome (AGS) is an autoinflammatory disorder resulting in sustained interferon activation through defects in nucleic acid modification and sensing pathways. Thus, mRNA-based vaccination used against SARS-CoV-2, raise disease-specific safety concerns. To assess interferon signaling, we tested mRNA SARS-CoV-2 vaccines in AGS whole blood samples. Interferon activation is measured through quantitation of interferon signaling gene (ISG) expression and is increased in AGS patients. There was no increase in ISG scores from baseline following treatment with the nucleoside modified mRNA formulation compared to an increase with unmodified. A patient-family survey reported that the vaccines were well tolerated. These findings suggest that COVID vaccination using nucleoside-modified forms of mRNA vaccines are unlikely to directly stimulate ISG expression in response to mRNA internalization in AGS tissues. With continued community spread, we recommend vaccination using nucleoside-modified mRNA vaccines in this rare disease group in individuals for whom vaccines were previously well tolerated.